European CNS specialist Neuraxpharm strengthens French business

European CNS specialist Neuraxpharm strengthens French business

Dr. Pierre-Hervé Brun appointed new General Manager of Neuraxpharm France

Paris, February 14th, 2019. Neuraxpharm France, the French affiliate of Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces the appointment of Dr. Pierre-Hervé Brun as General Manager.

With 30 years in the pharmaceutical industry, Dr. Brun brings extensive experience in business development, market access & commercial operations management. He started his career in R&D at Rhone-Poulenc Rorer and held various management roles at Negma-Lerads and Therabel. Previously at Aptalis Pharma (formerly Axcan Pharma), he served successively as Senior European Business Development Director and Deputy General Manager in charge of Commercial Operation and Market Access. Most recently, he assisted pharma and biotech companies to strengthen their commercial, business development and market access strategies.

Dr. Brun holds a Doctorate in Pharmacy & a Biology degree from the University of Paris V and VI, and a Master’s in Applied and Basic Toxicology from the University of Paris VII. He held board positions at AMLIS, the French Association of mid-sized pharma companies and the French Pharmaceutical Trade Association (LEEM).

Dr. Jörg Thomas Dierks, CEO of Neuraxpharm, said: “We are very pleased Pierre-Hervé has joined the team at Neuraxpharm France. His appointment is in line with our strategy to further strengthen the senior management team also with new country manager appointments, especially as France is one of the top 5 markets in Europe. The appointment of Dr. Brun as the new France GM will enable us to leverage and fully utilize the platform we have in the French market and grow our position in this target country.

Dr. Pierre-Hervé Brun, General Manager of Neuraxpharm France, added: “I am pleased to join Neuraxpharm at this exciting stage as the Company looks to the French market for growth and expansion. I look forward to working with this dynamic and talented team to build and maximise the potential of Neuraxpharm.”

Neuraxpharm France, former Laboratoires Biodim, and located in Paris, is a French specialty pharma company focused on the sale and marketing of branded pharmaceutical products in the CNS mainly used to treat anxiety disorders, including leading brands such as SERESTA® and TEMESTA®.

For further information please contact:

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Tel: +44 203 950 9144

Email: neuraxpharm@optimumcomms.com

 

About Neuraxpharm

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in Germany, Spain, Italy, France, Poland, Czech Republic, Slovakia and Hungary. Backed by funds advised by Apax Partners, Neuraxpharm has a unique understanding of the CNS market of over 30 years.

Neuraxpharm develops and commercializes in Europe branded and generic CNS pharmaceuticals and nutraceuticals, offering a wide range of effective, differentiated and affordable CNS treatments, aimed at patients as well as health professionals and industry partners.

Present in more than 50 countries, Neuraxpharm also manufactures pharmaceutical forms and active pharmaceutical ingredients indicated for the CNS and respiratory areas.

www.neuraxpharm.com

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH